Universitat Rovira i Virgili and Centro de Tecnología Química de Catalunya , Carrer de Marcellí Domingo s/n, 43007 Tarragona, Spain.
Medcom Advance S.A. , Av. Roma, 08840 Barcelona, Spain.
J Am Chem Soc. 2016 Nov 2;138(43):14206-14209. doi: 10.1021/jacs.6b08957. Epub 2016 Oct 18.
Blood-based biomarkers (liquid biopsy) offer extremely valuable tools for the noninvasive diagnosis and monitoring of tumors. The protein c-MYC, a transcription factor that has been shown to be deregulated in up to 70% of human cancers, can be used as a robust proteomic signature for cancer. Herein, we developed a rapid, highly specific, and sensitive surface-enhanced Raman scattering (SERS) assay for the quantification of c-MYC in real blood samples. The sensing scheme relies on the use of specifically designed hybrid plasmonic materials and their bioderivatization with a selective peptidic receptor modified with a SERS transducer. Peptide/c-MYC recognition events translate into measurable alterations of the SERS spectra associated with a molecular reorientation of the transducer, in agreement with the surface selection rules. The efficiency of the sensor is demonstrated in cellular lines, healthy donors and a cancer patient.
基于血液的生物标志物（液体活检）为肿瘤的非侵入性诊断和监测提供了极其有价值的工具。蛋白质 c-MYC 是一种转录因子，已被证明在多达 70%的人类癌症中失调，可用作癌症的强大蛋白质组学特征。在此，我们开发了一种快速、高度特异和敏感的表面增强拉曼散射（SERS）测定法，用于定量检测真实血液样本中的 c-MYC。该传感方案依赖于使用专门设计的混合等离子体材料及其与用 SERS 转导器修饰的选择性肽受体的生物衍生化。肽/c-MYC 识别事件转化为与转导器的分子重取向相关的可测量的 SERS 光谱变化，这与表面选择规则一致。该传感器在细胞系、健康供体和癌症患者中得到了验证。
